Who is sponsoring NCT01063270?

NCT01063270 is sponsored by Henry Ford Health System.

What drugs are being tested in NCT01063270?

Interventions in NCT01063270: Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment.

What condition does NCT01063270 study?

NCT01063270 studies Hidradenitis Suppurativa.

Is NCT01063270 still recruiting?

NCT01063270 is currently completed. Last updated 20 July 2022.

Last reviewed 2022-07-20 · How we verify

NCT01063270

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Control Trial Comparing Efficacy of Antibiotic Therapy Alone Versus Antibiotic Therapy in Conjunction With Quadruple Pulse Therapy Using NdYag Laser in Treatment of Hidradenitis Suppurativa

Completed NA Last updated 20 July 2022

What this trial tests

NA trial testing Clindamycin & Rifampin in Hidradenitis Suppurativa in 18 participants. Completed in 1 December 2013.

Timeline

1 February 2010

Primary endpoint
1 July 2011

1 December 2013

Quick facts

Lead sponsor	Henry Ford Health System
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	18
Start date	1 February 2010
Primary completion	1 July 2011
Estimated completion	1 December 2013
Sites	1 location across United States

Drugs / interventions tested

Clindamycin & Rifampin — full drug profile →
Clindamycin + Rifampin along with NdYag Laser treatment

Conditions studied

Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

Henry Ford Health System — full company profile →

Who can join

16 and older, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number and severity of lesions
Time frame: 5 total clinic visits over 6 month period

Sponsor's own description

The purpose of this research study is to further evaluate the efficacy of two treatment regimens for the treatment of hidradenitis suppurativa. This is a randomized controlled study. Patients will be randomly assigned to an arm of the study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for hidradenitis suppurativa.
Ingram JR, Woo PN, Chua SL, Ormerod AD, et al · · 2015 · cited 34× · PMID 26443004 · DOI 10.1002/14651858.cd010081.pub2

Verify or expand the search:

Other recruiting trials for Hidradenitis Suppurativa

Currently open trials in the same condition.

NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting

Other Henry Ford Health System trials

Trials by the same sponsor.

NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · NA · not yet recruiting
NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers · NA · recruiting
NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy · not yet recruiting
NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01063270 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
Last refreshed: 20 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01063270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing